TENAX THERAPEUTICS, INC.

TENX

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Oct 15, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Placebo	Phase 3	Coronary Artery Bypass Grafting	-
TNX-103	Phase 3	Pulmonary Hypertension	-
Levosimendan	Phase 2	Hypertension Pulmonary Secondary	-
perfluorocarbon emulsion (Oxycyte) infusion	Phase 2	Traumatic Brain Injury	-
Levosimendan 2.5 mg/ml Injectable Solution	Phase 2	Hypertension Pulmonary Secondary Heart Failure	-

Catalyst Timeline

1 upcoming, 0 past

⭐Phase 3Next

October 2026~TNX-103

Primary completion for TNX-103 trial (NCT05983250) in Pulmonary Hypertension

Regulatory Approvals

TENX News